Abstracts - faqs.org

Abstracts

Business, general

Search abstracts:
Abstracts » Business, general

DuPont is paying Merck $2.6 billion to buy out 50% stake in drug venture

Article Abstract:

Dupont Co. has announced that it will pay $2.6 billion for Merck & Co.Es portion of Dupont Merck Pharmaceutical Co. Kurt Landgraf, DupontEs executive vice president overseeing life sciences, stated that the pharmaceuticals unit would be a decisive factor in DupontEs life scienceEs rising about 35% of sales in 2002. Merck decided to divest itself of the unit, which made about $1.3 billion in sales in 1997, because Dupont wanted to build the business more quickly than did Merck. Mr. Landgraf stated that Dupont would take a one-time charge of about $1 billion because of the purchase.

Comment:

Dupont plans to pay $2.6 bil for Merck & Co.Es portion of Dupont Merck Pharmaceutical Co.

Author: Warren, Susan
Publisher: Dow Jones & Company, Inc.
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
Pharmaceutical Preparation Manufacturing, Pharmaceutical Preparations, Parent-to-subsidiary activities, Subsidiary-to-parent activities, Drugs, DuPont Merck Pharmaceutical Co.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


DuPont sees a lower profit for 2nd period

Article Abstract:

The CEO of DuPont Co., Charles Holliday, announced that the company's 1998 second-quarter earnings will fall by up to 15% compared to the same period in 1997. Mr. Holliday called DuPont's performance "totally unacceptable." The earnings will be far less that what experts on Wall Street expected. DuPont attributed the poor earnings to several problems such as bad weather that led to low agricultural chemical sales.

Comment:

Company's 1998 second-quarter earnings will fall by up to 15% compared to the same period in 1997

Author: Warren, Susan
Publisher: Dow Jones & Company, Inc.
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
Sales, profits & dividends

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


BetzDearborn stock soars while shares of Hercules drop

Article Abstract:

Hercules Inc.'s deal to pay a premium of 100% to acquire BetzDearborn Inc. led to a rise in BetzDearborn shares. However, the deal led to a drop in Hercules' stock. Many saw Hercules' acquisition of BetzDearborn, a specialty-chemicals firm, as a major strategical victory. However, the purchase price of $72 per share, together with Hercules' assumption of $700 million in debt, hurt the company's share value.

Comment:

Hercules purchase of BetzDearborn increases BetzDearborn's share value but hurts Hercules' stock

Author: Warren, Susan
Publisher: Dow Jones & Company, Inc.
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
Asset sales & divestitures, Acquisitions & mergers, Other Commercial and Service Industry Machinery Manufacturing, Water & Waste Treatment Equip, Hercules Inc., BetzDearborn Inc.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Chemicals, E.I. du Pont de Nemours and Co., Article
Similar abstracts:
  • Abstracts: Qwest is acquiring LCI for $4.43 billion, creating No. 4 long-distance provider. BellSouth pushes harder in Latin America
  • Abstracts: Nabisco to take $406 million charge, cut 6% of work force in retrenchment. Vlasic hopes new marketing plan will perk up sales
  • Abstracts: British Air's new no-frills carrier, Go, to battle its discount rivals. AMR-British air linkup just keeps circling, circling
  • Abstracts: DuPont puts stock in global security force. DuPont Merck sued over licensing deal. DuPont buys out Merck
  • Abstracts: CBS affiliates to share costs for first time. High-stakes battle for momentum. Can football revive CBS?
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.